Open Access Peer-Reviewed
Carta ao Editor

Fluorofenidone inhibits the epithelial-mesenchymal transition in human lens epithelial cell line FHL 124: a promising therapeutic strategy against posterior capsular opacification

Fluorofenidona inibe a transição epitelio-mesenquimal em linhagem de células epiteliais FHL 124 de cristalino humano: uma estratégia terapêutica promissora contra a opacificação capsular posterior

Michael Wormstone

DOI: 10.5935/0004-2749.20210088

Dear Editor:

I have recently read an article in your journal by Zhuang et al.(1) and became interested in this work, specifically because as indicated in the title, the lens cell line FHL124 was used as an experimental model. I was curious to read in the Methods section that the authors obtained these cells from American Type Culture Collection (ATCC). As far as I am aware, FHL124 cells are not commercially available. Upon accessing the ATCC website and searching for lens cells, only human lens epithelial (HLE-B3) are available for sale. Indeed, the latter are virally transformed, whereas FHL124 cells are spontaneously transformed and better reflect observations in tissue culture models(2). Therefore, the authors should confirm that the cells they have used are indeed FHL124 and not HLE-B3 and, if so, clearly present the source of their FHL124 cells.

Kind regards,

 

REFERENCES

1. Zhuang H, Zheng NX, Lin L, Zhang WZ, Zhang WY, Yu QQ, et al. Fluorofenidone inhibits epithelial-mesenchymal transition in human lens epithelial cell line FHL 124: a promising therapeutic strategy against posterior capsular opacification. Arq Bras Oftalmol. 2021:S0004-27492021005001227. doi: 10.5935/0004-2749.20210040.

2. Wormstone IM, Eldred JA. Experimental models for posterior capsule opacification research. Exp Eye Res. 2016;142(1):2-12.

Submitted for publication: February 12, 2021.
Accepted for publication: February 19, 2021.

Funding: This study received no specific financial support.

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose.


Dimension

© 2024 - All rights reserved - Conselho Brasileiro de Oftalmologia